Avalon GloboCare and its Subsidiary Genexosome Technologies Announce Discovery and Development of World's First Saliva-Based Exosomal Biomarker "miR-185" as Dual Diagnostic and Therapeutic Target for Oral Cancer

Stock Information for Avalon GloboCare Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avalon GloboCare Corp.

Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines
Avalon GloboCare Provides Updates on its Lead Clinical Programs in CAR-T Therapy and Exosome-Based Regenerative Therapeutics
Avalon GloboCare Appoints Dr. Yen-Michael Sheng Hsu, Founding Director of cGMP Cellular Therapy Facility at Weill Cornell Medicine, to its Scientific and Clinical Advisory Board
Avalon GloboCare Expected to Join the Russell 3000® Index
Avalon GloboCare President and CEO David Jin, M.D., Ph.D. to Chair the "Research and Application of Stem Cell Exosomes" Session at This Year's Second International Aesthetic Industry Conference
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization
Avalon GloboCare Partners with MIT to Develop Innovative AI-Enhanced Protein Design Technology in Cellular Therapy
Avalon GloboCare Announces $6 Million Registered Direct Offering with Institutional Investors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.